Tables
- Table 1. Studies describing the use of high-dose intravenous methylprednisolone in allergic bronchopulmonary aspergillosis
Fist author [ref.] Patients Age years M/F Risk factor Mean serum IgE IU·mL−1 Methylprednisolone dose Steroid duration Outcomes Side-effects Thomson [9] 4 6.075 (1.7–8.2) 3/1 CF 2950.5 20 mg·kg−1 every 4 weeks 4 years 3 out of 4 patients had clinical stabilisation Hypertension and hyperglycaemia in one patient each Cohen-Cymberknoh [10] 9 17.1 (7–36) 4/5 CF 542 10–15 mg·kg−1 (max 1 g) every 4 weeks 6–10 months Significant improvement in FEV1 and decreased IgE in all cases Weight gain and psychiatric disorder in one patient each Thomas [11] 1 11 1/0 CF 9178 20 mg·kg−1 for 3 days followed by 10 mg·kg−1 for 3 days 6 days Clinical stabilisation Skov [12] 25 19.9 (10–34) 16/9 CF NA 15 mg·kg−1 3–7 months Clinical stabilisation; reduction in the number of exacerbations Minimal side-effects Data are presented as n or mean (range), unless otherwise stated. M: males; F: females; CF: cystic fibrosis; NA: not available; FEV1: forced expiratory volume in 1 s.
Vol 23 Issue 131
Table of Contents
Pulse methylprednisolone in allergic bronchopulmonary aspergillosis exacerbations
